Journal of stomatology, oral and maxillofacial surgery · 2026
Complete response of inoperable tonsillar follicular dendritic cell sarcoma treated with electrochemotherapy: First case report and literature review.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chiari Francesco, Caporale Claudio Donadio, Cordeschi Sara, Guarino Pierre
Аннотация
BACKGROUND: Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm arising from follicular dendritic cells, with a predilection for extranodal sites. FDCS of the tonsil is exceptionally uncommon, and no standardized treatment exists for patients with locally advanced or inoperable disease, particularly when conventional therapies are contraindicated.
CASE PRESENTATION: We report the case of an 80-year-old woman with localized FDCS of the left palatine tonsil who was ineligible for surgery or systemic therapy due to severe comorbidities. Electrochemotherapy (ECT) with bleomycin was administered under general anesthesia following ESOPE guidelines. The treatment was well tolerated without complications. At two weeks post-treatment, marked tumor reduction and necrosis were observed, and a complete clinical and radiological response was documented at 2 months, and maintained at 12 months of follow-up.
CONCLUSIONS: To our knowledge, this is the first documented case of tonsillar FDCS treated with ECT. This experience suggests that ECT may represent a valuable local treatment option for selected patients with inoperable FDCS, warranting further investigation of its role in managing rare soft tissue sarcomas.
CASE PRESENTATION: We report the case of an 80-year-old woman with localized FDCS of the left palatine tonsil who was ineligible for surgery or systemic therapy due to severe comorbidities. Electrochemotherapy (ECT) with bleomycin was administered under general anesthesia following ESOPE guidelines. The treatment was well tolerated without complications. At two weeks post-treatment, marked tumor reduction and necrosis were observed, and a complete clinical and radiological response was documented at 2 months, and maintained at 12 months of follow-up.
CONCLUSIONS: To our knowledge, this is the first documented case of tonsillar FDCS treated with ECT. This experience suggests that ECT may represent a valuable local treatment option for selected patients with inoperable FDCS, warranting further investigation of its role in managing rare soft tissue sarcomas.